TY - JOUR
T1 - The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods
AU - Calvani, Riccardo
AU - Rodriguez-Mañas, Leocadio
AU - Picca, Anna
AU - Marini, Federico
AU - Biancolillo, Alessandra
AU - Laosa, Olga
AU - Pedraza, Laura
AU - Gervasoni, Jacopo
AU - Primiano, Aniello
AU - Miccheli, Alfredo
AU - Bourdel-Marchasson, Isabelle
AU - Regueme, Sophie C.
AU - Bernabei, Roberto
AU - Marzetti, Emanuele
AU - Sinclair, Alan J.
AU - Gambassi, Giovanni
PY - 2020
Y1 - 2020
N2 - Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact geriatric condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM.
AB - Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact geriatric condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM.
KW - Chemometrics
KW - Metabolic profiling
KW - Metabolomics
KW - Multivariate analysis
KW - Personalized medicine
KW - Sarcopenia
KW - Chemometrics
KW - Metabolic profiling
KW - Metabolomics
KW - Multivariate analysis
KW - Personalized medicine
KW - Sarcopenia
UR - http://hdl.handle.net/10807/164733
U2 - 10.1016/j.exger.2019.110782
DO - 10.1016/j.exger.2019.110782
M3 - Article
SN - 0531-5565
SP - 110782-N/A
JO - Experimental Gerontology
JF - Experimental Gerontology
ER -
